Double-blind study of the actively transported levodopa prodrug XP21279 in Parkinson's disease

Movement Disorders

Volumn 29, Issue 1, 2014, Pages 75-82

  Lewitt, Peter A ^a,b   Huff, F Jacob ^c   Hauser, Robert A ^d   Chen, Dan ^c   Lissin, Dmitri ^c   Zomorodi, Katie ^c   Cundy, Kenneth C ^c  

^a HENRY FORD HOSPITAL   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c XenoPort Inc   (United States)

^d UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Dyskinesias; Levodopa; Motor fluctuations; Parkinson's disease; Pharmacokinetics; XP21279

Indexed keywords

ANTIPARKINSON AGENT; CARBIDOPA; CARBIDOPA PLUS LEVODOPA; UNCLASSIFIED DRUG; XP 21279; XP 21279 PLUS CARBIDOPA;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; DYSKINESIA; FEMALE; GASTROESOPHAGEAL REFLUX; HUMAN; INSOMNIA; MAINTENANCE THERAPY; MALE; MAXIMUM PLASMA CONCENTRATION; MIDDLE AGED; MORNING DOSAGE; MOTOR DYSFUNCTION; MULTICENTER STUDY; OUTCOME ASSESSMENT; PARKINSON DISEASE; PHASE 2 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; SUSTAINED DRUG RELEASE; TREATMENT DURATION; UNIFIED PARKINSON DISEASE RATING SCALE; UNSPECIFIED SIDE EFFECT;

DYSKINESIAS; LEVODOPA; MOTOR FLUCTUATIONS; PARKINSON'S DISEASE; PHARMACOKINETICS; XP21279;

ANTIPARKINSON AGENTS; CARBIDOPA; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; PRODRUGS; TREATMENT OUTCOME;

EID: 84892931747     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25742     Document Type: Article

References (19)

1. LeWitt PA. Levodopa for the treatment of Parkinson's disease. N Engl J Med 2008;359:2468-2476.
2. Merck & Company, Inc. Sinemet (carbidopa-levodopa) [prescribing information]. Whitehouse Station, NJ: Merck & Company, Inc.; 2011.
3. LeWitt PA, Jennings D, Lyons KE, et al. Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies. Mov Disord 2009;24:1319-1324.
4. Pahwa R, Factor SA, Lyons KE, et al; Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006;66:983-995.
5. Chan PL, Nutt JG, Holford NH. Pharmacokinetic and pharmacodynamic changes during the first four years of levodopa treatment in Parkinson's disease. J Pharmacokinet Pharmacodyn 2005;32:459-484.
6. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001;16:448-458.
7. Nyholm D. Pharmacokinetic optimisation in the treatment of Parkinson's disease: an update. Clin Pharmacokinet 2006;45:109-136.
8. Stocchi F, Tagliati M, Olanow CW. Treatment of levodopa-induced motor complications. Mov Disord 2008;23:S599-S612.
9. Aton Pharma, Inc. Lodosyn (carbidopa) tablet [package insert]. Bridgewater, NJ: Aton Pharma, Inc.; 2011.
10. LeWitt PA, Ellenbogen A, Chen D, et al. Actively-transported levodopa prodrug XP21279: a study in patients with Parkinson disease who experience motor fluctuations. Clin Neuropharm 2012;35:103-110.
11. Hauser RA, Friedlander J, Zesiewicz TA, et al. A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia. Clin Neuropharmacol 2000;23:75-81.
12. Fahn S, Elton RL; members of the UPDRS Development Committee. The Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, editors. Recent Developments in Parkinson's Disease, Vol. 2. Florham Park, NJ: Macmillan Healthcare Information; 1987:153-163.
13. Peto V, Jenkinson C, Fitzpatrick R, Greenhall R. The development and validation of a short measure of functioning and well being for individuals with Parkinson's disease. Qual Life Res 1995;4:241-248.
14. Guy W. ECDEU Assessment Manual for Psychopharmacology. Publication no. (ADM) 76-338. Rockville, MD: National Institute of Mental Health, US Department of Health, Education, and Welfare; 1976. Available at: http://ia700503.us.archive.org/10/items/ecdeuassessmentm1933guyw/ecdeuassessmentm1933guyw.pdf. Accessed February 1, 2013.
15. Kurth MC, Tetrud JW, Tanner CM, et al. Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with "on-off" fluctuations. Neurology 1993;43:1698-1703.
16. Cook RD. Influential observations in linear regression. J Am Stat Assoc 1979;74:169-174.
17. Poewe WH, Deuschl G, Gordin A, Kultalahti ER, Leinonen M; Celomen Study Group. Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol Scand 2002;105:245-255.
18. Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 2005;62:241-248.
19. Rascol O. Rasagiline in the pharmacotherapy of Parkinson's disease-a review. Expert Opin Pharmacother 2005;6:2061-2075.